Overcoming post-transplant graft failure and adenovirus infection in a patient with FLT3 -TKD-mutated mixed-phenotype acute leukemia: A case report.
Yusuke TakadaShuhei KurosawaToshimitsu UekiYuho NajimaSatoshi WakitaHiroki YamaguchiTakako YokotaMasaki HibiAyumi HiraharaTsutomu YoshidaSo OkuboMoe MasudaHitomi NakayamaAki SakuraiChisako ItoYoshinobu AisaTomonori NakazatoPublished in: EJHaem (2024)
Mixed-phenotype acute leukemia (MPAL) with FLT3 -TKD mutations is a rare and challenging subtype of leukemia. Effective management strategies are crucial for improving patient outcomes. A 31-year-old man with FLT3 -TKD-mutated MPAL achieved hematological remission through the JALSG ALL202-O protocol and gilteritinib, followed by cord blood transplantation (CBT). Post-transplant complications included adenovirus-induced hemorrhagic cystitis, managed with bladder irrigation and ribavirin, and engraftment failure, necessitating a second CBT on Day 35. Subsequent adenoviral conjunctivitis resolved with vidarabine. The patient achieved neutrophil engraftment by Day 76 and was discharged on Day 173 without relapse. This case highlights the importance of vigilant supportive care and tailored therapy in managing MPAL with FLT3 mutations, especially in the context of post-transplant complications.
Keyphrases
- acute myeloid leukemia
- cord blood
- tyrosine kinase
- case report
- healthcare
- risk factors
- randomized controlled trial
- spinal cord injury
- palliative care
- high glucose
- quality improvement
- diabetic rats
- stem cells
- rheumatoid arthritis
- chronic pain
- oxidative stress
- pain management
- disease activity
- systemic lupus erythematosus
- water quality
- ulcerative colitis
- health insurance
- replacement therapy